Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and meta-analysis of randomized controlled trials. J Vasc Intervent Radiol 2020; 31: 202-212
Published: 29th April 2020
Authors: Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Paraskevopoulos I, Karnabatidis D et al.
This updated meta-analysis included eight RCTs of 1420 procedures, followed for one year. Cumulative risk of death/amputation was significantly worse following the use of paclitaxel-coated balloons: 13.7 versus 9.4 per cent, P = 0.008.Pubmed Link
You may also be interested in
Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018; 24: e011245.
Authors: Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D
Infrapopliteal angioplasty of one or more than one artery for critical limb ischaemia: a randomised clinical trial. Eur J Vasc Endovasc Surg 2018; 55: 518-527.
Authors: Biagioni RB, Biagioni LC, Nasser F, Burihan MC, Ingrund JC, Neser A et al.
Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med 2018; 378: 603-614.
Authors: Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin S-S et al.
Low-dose paclitaxel–coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease. Circulation. 2017; 135: 2227-2236.
Authors: Schroeder H, Werner M, Meyer D-R, Reimer P, Krüger K, Jaff MR et al.
Randomized comparison of paclitaxel-eluting balloon and stenting versus plain balloon plus stenting versus directional atherectomy for femoral artery disease (ISAR-STATH). Circulation. 2017; 135: 2218-2226.
Authors: Ott I, Cassese S, Groha P, Steppich B, Hadamitzky M, Ibrahim T et al.
Paclitaxel-coated balloon reduces target lesion revascularization compared with standard balloon angioplasty. J Vasc Surg 2017; 65: 558–570.
Authors: Candy N, Ng E, Velu R
A network meta-analysis of randomized controlled trials comparing treatment modalities for de novo superficial femoral artery occlusive lesions. J Vasc Surg 2017; 65: 234–245.
Authors: Antonopoulos CN, Mylonas SN, Moulakakis KG, Sergentanis TN, Sfyroeras GS, Lazaris AM et al.
Primary stenting of the superficial femoral artery in intermittent claudication improves health related quality of life, ABI and walking distance: 12 month results of a controlled randomised multicenter trial. Eur J Vasc Endovasc Surg 2017; 53: 686-694.
Authors: Lindgren H, Qvarfordt P, Akesson M, Bergman S, Gottsater A, Jansson I et al.
Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 2017; 389: 1312–1322.
Authors: Nijssen EC, Rennenberg RJ , Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA et al.
Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts. J Vasc Surg 2016; 64: 1400-1410.
Authors: Vesely T, DaVanzo W, Behrend T, Dwyer A, Aruny J
Durability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment of aortoiliac occlusive disease. J Vasc Surg 2016; 64: 83-94.
Authors: Mwipatayi BP, Sharma S, Daneshmand A, Thomas SD, Vijayan V, Altaf N et al.
Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery. 5-year results of the Zilver PTX randomized trial. Circulation 2016; 133: 1472-1483.
Authors: Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB et al.